AnaptysBio, Inc.

ANAB

$34.77

Name : AnaptysBio, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $972,621,184.00

EPSttm : -2.82

AnaptysBio, Inc.

$34.77

2.81%

$0.95

Float Short %

27.06

Margin Of Safety %

Put/Call OI Ratio

5.28

EPS Next Q Diff

-1.48

EPS Last/This Y

2.66

EPS This/Next Y

-0.99

Price

34.75

Target Price

Analyst Recom

1.25

Performance Q

75.69

Relative Volume

2.25

Beta

0.32

Ticker: ANAB

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	ANAB	35.28	2.42	0.28	9130
2025-10-21	ANAB	34.07	2.41	0.00	9147
2025-10-22	ANAB	33.68	2.40	0.06	9149
2025-10-23	ANAB	33.99	2.39	0.00	9164
2025-10-24	ANAB	35.06	2.39	4.80	9165
2025-10-27	ANAB	36.16	2.39	0.10	9173
2025-10-28	ANAB	36.12	2.38	0.67	9181
2025-10-29	ANAB	36.15	2.38	1.56	9173
2025-10-30	ANAB	36.47	2.37	5.00	9184
2025-10-31	ANAB	36.61	2.37	0.00	9195
2025-11-03	ANAB	36	2.37	32.25	9193
2025-11-04	ANAB	34.69	2.42	0.29	9318
2025-11-05	ANAB	35.99	2.40	0.59	9350
2025-11-06	ANAB	38.17	2.36	0.29	9400
2025-11-07	ANAB	39.68	2.36	320.77	9530
2025-11-10	ANAB	33.98	3.72	27.32	13433
2025-11-11	ANAB	33.4	5.11	5.58	17879
2025-11-12	ANAB	33.04	5.20	25.25	18262
2025-11-13	ANAB	33.27	5.23	0.00	18362
2025-11-14	ANAB	33.81	5.22	0.21	18367
2025-11-17	ANAB	34.7	5.28	0.01	18333
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	ANAB	35.28	-32.6	27.6	-4.60
2025-10-21	ANAB	34.08	-32.6	30.0	-4.60
2025-10-22	ANAB	33.65	-32.6	29.0	-4.60
2025-10-23	ANAB	33.99	-32.6	28.0	-4.60
2025-10-24	ANAB	35.01	-32.6	27.1	-4.60
2025-10-27	ANAB	36.15	-32.6	27.0	-4.60
2025-10-28	ANAB	36.16	-32.6	28.4	-4.60
2025-10-29	ANAB	36.12	-32.6	28.5	-4.60
2025-10-30	ANAB	36.47	-32.6	28.1	-4.60
2025-10-31	ANAB	36.61	-32.6	28.1	-4.60
2025-11-03	ANAB	36.05	-9.7	29.1	-4.34
2025-11-04	ANAB	34.77	-9.7	30.0	-4.34
2025-11-05	ANAB	35.97	-9.7	26.8	-4.34
2025-11-06	ANAB	38.19	-9.7	-29.3	-4.34
2025-11-07	ANAB	39.65	-9.7	-28.2	-4.34
2025-11-10	ANAB	33.98	13.7	-45.2	-4.34
2025-11-11	ANAB	33.56	13.7	-55.9	-4.17
2025-11-12	ANAB	33.06	13.7	-55.6	-4.17
2025-11-13	ANAB	33.24	13.7	-57.3	-1.19
2025-11-14	ANAB	33.87	233.3	-23.8	-1.19
2025-11-17	ANAB	34.75	100.6	-24.2	-2.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	ANAB	-1.86	-9.40	27.98
2025-10-21	ANAB	-1.86	-9.40	27.98
2025-10-22	ANAB	-1.86	-9.40	27.98
2025-10-23	ANAB	-1.86	-9.40	27.98
2025-10-24	ANAB	-1.86	-9.40	27.98
2025-10-27	ANAB	-1.86	-9.90	27.76
2025-10-28	ANAB	-1.86	-9.90	27.76
2025-10-29	ANAB	-1.86	-9.90	27.76
2025-10-30	ANAB	-1.86	-9.90	27.76
2025-10-31	ANAB	-1.86	-9.90	27.76
2025-11-03	ANAB	-1.86	-9.48	27.76
2025-11-04	ANAB	-1.86	-9.48	27.76
2025-11-05	ANAB	-1.86	-9.48	27.76
2025-11-06	ANAB	-1.88	-9.48	27.76
2025-11-07	ANAB	-1.88	-9.48	28.07
2025-11-10	ANAB	-1.88	-8.97	28.07
2025-11-11	ANAB	-1.88	-8.97	28.07
2025-11-12	ANAB	-1.88	-8.97	27.06
2025-11-13	ANAB	-1.88	-8.97	27.06
2025-11-14	ANAB	-1.88	-8.97	27.06
2025-11-17	ANAB	-1.88	-4.26	27.06
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

-0.96

Insider Transactions

-1.88

Institutional Transactions

-4.26

Beta

0.32

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

15.9

Max Drawdown 5-Year %

-69.3

Target Price

P/E

Forward P/E

PEG

P/S

5.68

P/B

P/Free Cash Flow

EPS

-2.82

Average EPS Est. Cur. Y

-2.46

EPS Next Y. (Est.)

-3.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-49.94

Relative Volume

2.25

Return on Equity vs Sector %

260.7

Return on Equity vs Industry %

275.7

EPS 1 7Days Diff

1.7

EPS 1 30Days Diff

2.14

EBIT Estimation

-24.2

AnaptysBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 136

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

stock quote shares ANAB – AnaptysBio Inc Stock Price stock today

news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ANAB – AnaptysBio Inc yahoo finance google finance

stock history ANAB – AnaptysBio Inc invest stock market

stock prices ANAB premarket after hours

ticker ANAB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ANAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y